Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma, Gastroenterology. déc, vol.151, issue.6, pp.1155-1163, 2016. ,
Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis, Eur J Nucl Med Mol Imaging. avr, vol.43, issue.4, pp.635-678, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01217979
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, noncomparative, phase 1/2 dose escalation and expansion trial. The Lancet, vol.389, pp.2492-502, 2017. ,
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial, Lancet Oncol. juill, vol.19, issue.7, pp.940-52, 2018. ,
LBA3 -IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC), Annals of Oncology, vol.30, pp.186-193, 2019. ,
Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis, JNCI Journal of the National Cancer Institute. 29 mai, vol.106, issue.6, pp.124-124, 2014. ,
Radiosensitivity of CD4 or CD8 positive human Tlymphocytes by an in vitro colony formation assay, Radiat Res. août, vol.123, issue.2, pp.224-231, 1990. ,
Minimum absolute lymphocyte counts during radiation are associated with a worse prognosis in patients with unresectable hepatocellular carcinoma, Therap Adv Gastroenterol. févr, vol.10, issue.2, pp.231-272, 2017. ,
Impaired lymphocyte function in patients with hepatic malignancies after selective internal radiotherapy, Cancer Immunol Immunother. mai, vol.67, issue.5, pp.843-53, 2018. ,
Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma, Gut. févr, vol.68, issue.2, pp.335-381, 2019. ,
Combined locoregionalimmunotherapy for liver cancer, J Hepatol. mai, vol.70, issue.5, pp.999-1007, 2019. ,
Combining Radiotherapy and Cancer Immunotherapy: A Paradigm Shift, JNCI Journal of the National Cancer Institute. 20 févr, vol.105, issue.4, pp.256-65, 2013. ,
Research reporting standards for radioembolization of hepatic malignancies, J Vasc Interv Radiol. mars, vol.22, issue.3, pp.265-78, 2011. ,
Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept, Eur J Nucl Med Mol Imaging. juill, vol.40, issue.7, pp.1057-68, 2013. ,
Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis, J Nucl Med. mars, vol.56, issue.3, pp.339-385, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01128116
Hepatic Arterial Bland Embolization Increases Th17 Cell Infiltration in a Syngeneic Rat Model of Hepatocellular Carcinoma, Cardiovasc Intervent Radiol, 2019. ,
Cytokines and (90)Y-Radioembolization: Relation to Liver Function and Overall Survival, Cardiovasc Intervent Radiol. août, vol.40, issue.8, pp.1185-95, 2017. ,
A dosimetric treatment planning strategy in radioembolization of hepatocarcinoma with 90Y glass microspheres, Q J Nucl Med Mol Imaging. déc, vol.56, issue.6, pp.503-511, 2012. ,
Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score), Eur J Cancer, vol.84, pp.212-220, 2017. ,
Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab, J Immunother Cancer. 16 juill, vol.6, issue.1, p.74, 2018. ,